CatalystMarker
← board

EIKN

Eikon Therapeuticsdistress 4/10 · elevated risk
$9.600%today-41% from 52w high
eikontx.com384 employeesFounded 2019Millbrae, CABiotechnology
Lead: Advanced Solid Tumors
Revenue
pre-revenue
Liquidity
$596M
Runway
1.7 yrs
Shares 1y
—

Price & events

-36.0% over 6M
$8.36$12.31$16.26Feb 26Apr 26Jul 264.9Mdilution: 424B4 offering (2026-02-05)rating: Wedbush: Underperform (2026-05-12)rating: Wedbush: Underperform (2026-03-31)rating: Cantor Fitzgerald: Overweight (2026-03-02)rating: JP Morgan: Overweight (2026-03-02)rating: B of A Securities: Buy (2026-03-02)rating: Mizuho: Outperform (2026-03-02)rating: Morgan Stanley: Overweight (2026-03-02)rating: Wedbush: Underperform (2026-02-26)
CatalystRating changeDilutionFinancingdashed = today
-0.1%
1D
-3.5%
1W
+0.9%
1M
-10.3%
3M
—
6M
—
1Y
—
2Y
—
5Y
-36.0%
All

Overview

Market Cap
$519.71M
Volume
6.75K
52 Week Range
$8.36 – $16.26
Total Shares
54.14M
Float Shares
29.84M
Short %
11.37%
% Held by Insiders
17.39%
% Held by Institutions
64.52%
RVOL
0.02x

Pipeline stages · 5 programs

EL219, Active Comparator- IV Antifungal (LAmB or voriconazole)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-12
EIK1001, Pembrolizumab, Paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-12
IMP1734
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-06-01
EIK1004-001 (IMP1707-001)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-12
EIK1001, Pembrolizumab (KEYTRUDA®), Paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-03

Pipeline · 7 trials · 7 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-12
Estimated 50%
readout ~2027-01-15
Phase 2EL219, Active Comparator- IV Antifungal (LAmB or voriconazole)Invasive Mould Infection—recruiting
2026-12
Estimated 50%
readout ~2027-01-15
Phase 2EIK1001, Pembrolizumab, PaclitaxelNSCLC—active not recruiting
2027-06-01
Estimated 50%
readout ~2027-07-16
Phase 1/2IMP1734Advanced Solid Tumor—recruiting
2028-12
Estimated 50%
readout ~2029-01-15
Phase 1/2EIK1004-001 (IMP1707-001)Advanced Solid Tumors—recruiting
2029-03
Estimated 50%
readout ~2029-04-15
Phase 1/2EIK1005, pembrolizumab (KEYTRUDA® )Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors—recruiting
Show all 7 trials · 2 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2035-12
Estimated 50%
readout ~2036-02-14
Phase 2/3EIK1001, Pembrolizumab (KEYTRUDA® )Advanced Melanoma—recruiting
2035-12-31
Estimated 50%
readout ~2036-03-15
Phase 2/3EIK1001, Pembrolizumab (KEYTRUDA®), PaclitaxelNon Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC—recruiting

Catalyst news & presentations · 7

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 54,138,628 · 1 offerings/1y · 0 PIPEs
  • 2026-02-05424B4offering
  • 2026-01-30EFFECTshelf_effective
  • 2026-01-28S-1/Ashelf_registration
  • 2026-01-09S-1shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2026-05-12WedbushUnderperform
  • 2026-03-31WedbushUnderperform
  • 2026-03-02Cantor FitzgeraldOverweight
  • 2026-03-02JP MorganOverweight
  • 2026-03-02B of A SecuritiesBuy
  • 2026-03-02MizuhoOutperform

Competitors — Advanced Solid Tumors

  • ABBVAbbVie Inc.$451.1B · D2
  • MRKMerck & Co., Inc.$318.8B · D3
  • NVSEFNOVARTIS AG$292.0B · D3
  • AMGNAMGEN INC$195.4B · D3
  • CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
  • CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
  • BCYCBICYCLE THERAPEUTICS PLC$124M · D4
  • XLOXilio Therapeutics, Inc.$50M · D1
  • APREAprea Therapeutics, Inc.$8M · D6

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.